The US National Cancer Institute is a long-time, committed research and clinical development partner. Our collaboration efforts began under Dr. Rosenberg’s immunology Laboratory and continue today with the endocrine oncology branch of the cancer center. Dr. Steven Libutti, former a surgeon at the NCI and now the Director of the Rutgers Cancer Institute of New Jersey, conducted the company’s phase 1 clinical trial. Oncologist and surgeon, Dr. Naris Nilubol, will be managing CytImmune’s upcoming clinical studies at the NCI. Included in these studies will be efficacy assessments of CYT-6091 in combination with nab-paclitaxel (Abraxane). We anticipate these studies will begin in late 2021 or early 2022.

CytImmune recently signed an agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune diseases to investigate and confirm synergies between TNF alpha and existing immunotherapies. Additional research and development work may also be conducted in collaboration with CytImmune on our new 2nd generation immuno oncology nanomedicines. This work will be completed in the laboratory of the Dr. Kouji Matsushima, reknowned immunologist and former President of the International Cytokine Society.